1. Home
  2. DCTH vs MYGN Comparison

DCTH vs MYGN Comparison

Compare DCTH & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$12.59

Market Cap

372.5M

Sector

Health Care

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$5.71

Market Cap

444.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCTH
MYGN
Founded
1988
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
372.5M
444.2M
IPO Year
2015
1996

Fundamental Metrics

Financial Performance
Metric
DCTH
MYGN
Price
$12.59
$5.71
Analyst Decision
Strong Buy
Buy
Analyst Count
4
7
Target Price
$22.00
$7.64
AVG Volume (30 Days)
579.8K
1.7M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
107.53
N/A
EPS
N/A
N/A
Revenue
N/A
$771,400,000.00
Revenue This Year
$24.54
$6.86
Revenue Next Year
$33.15
$5.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.33
52 Week Low
$8.12
$3.53
52 Week High
$13.44
$8.59

Technical Indicators

Market Signals
Indicator
DCTH
MYGN
Relative Strength Index (RSI) 63.23 72.85
Support Level $10.26 $4.29
Resistance Level N/A $7.29
Average True Range (ATR) 0.57 0.34
MACD 0.12 0.16
Stochastic Oscillator 76.05 87.53

Price Performance

Historical Comparison
DCTH
MYGN

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: